TNF and steatosis: Interestingly, in rodents, the preclinical molecule (GFT-505) demonstrated protective effects against steatosis, inflammation, and fibrosis through inhibition of pro-inflammatory cytokine [Tumor Necrosis Factor alpha (TNF-α) and Interleukin (IL)-1β] and profibrotic gene expression (tissue inhibitor of metalloproteinases 2, transforming growth factor-β, collagen type Iα1, and collagen type IIα2) [96].